 Marco De Dominici
Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2023 | 279 | 1.530 |
Why?
| | Cyclin-Dependent Kinase 6 | 3 | 2021 | 40 | 1.400 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2022 | 31 | 0.770 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 3 | 2018 | 232 | 0.690 |
Why?
| | Skin | 2 | 2023 | 725 | 0.650 |
Why?
| | Hematopoietic Stem Cells | 4 | 2024 | 382 | 0.590 |
Why?
| | Skin Neoplasms | 2 | 2023 | 830 | 0.590 |
Why?
| | Recombinant Fusion Proteins | 1 | 2020 | 650 | 0.550 |
Why?
| | Protein Kinase Inhibitors | 3 | 2021 | 886 | 0.490 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2271 | 0.460 |
Why?
| | Proto-Oncogene Proteins c-myb | 4 | 2021 | 10 | 0.450 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2018 | 118 | 0.410 |
Why?
| | Clone Cells | 2 | 2023 | 262 | 0.370 |
Why?
| | Gene Expression Regulation, Leukemic | 3 | 2021 | 50 | 0.340 |
Why?
| | STAT5 Transcription Factor | 2 | 2018 | 48 | 0.270 |
Why?
| | Neoplasms | 1 | 2021 | 2454 | 0.260 |
Why?
| | Tumor Suppressor Proteins | 2 | 2018 | 311 | 0.230 |
Why?
| | Stem Cell Niche | 1 | 2024 | 53 | 0.220 |
Why?
| | Cell Proliferation | 4 | 2020 | 2378 | 0.210 |
Why?
| | Fusion Proteins, bcr-abl | 4 | 2021 | 69 | 0.200 |
Why?
| | Antineoplastic Agents | 3 | 2021 | 2045 | 0.200 |
Why?
| | DNA Modification Methylases | 1 | 2022 | 13 | 0.200 |
Why?
| | Mice | 11 | 2021 | 16983 | 0.190 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 808 | 0.190 |
Why?
| | Lymphoma, B-Cell | 1 | 2023 | 103 | 0.190 |
Why?
| | MicroRNAs | 2 | 2018 | 680 | 0.190 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 37 | 0.180 |
Why?
| | Molecular Targeted Therapy | 2 | 2021 | 391 | 0.180 |
Why?
| | Genes, cdc | 1 | 2020 | 10 | 0.170 |
Why?
| | Chromatin | 2 | 2021 | 478 | 0.170 |
Why?
| | Cell Line, Tumor | 4 | 2020 | 3185 | 0.160 |
Why?
| | Apoptosis | 5 | 2020 | 2489 | 0.160 |
Why?
| | Interleukin-1beta | 1 | 2021 | 369 | 0.160 |
Why?
| | Molecular Structure | 1 | 2020 | 483 | 0.150 |
Why?
| | Blast Crisis | 1 | 2018 | 33 | 0.150 |
Why?
| | Animals | 12 | 2024 | 35409 | 0.150 |
Why?
| | RNA, Neoplasm | 1 | 2018 | 82 | 0.150 |
Why?
| | Enzyme Activation | 1 | 2020 | 813 | 0.150 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2016 | 48 | 0.150 |
Why?
| | Phosphorylation | 2 | 2020 | 1716 | 0.140 |
Why?
| | Multigene Family | 1 | 2018 | 195 | 0.140 |
Why?
| | Gene Silencing | 1 | 2018 | 190 | 0.140 |
Why?
| | Cell Cycle | 1 | 2020 | 583 | 0.140 |
Why?
| | Celecoxib | 1 | 2016 | 39 | 0.130 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2017 | 60 | 0.130 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2016 | 62 | 0.130 |
Why?
| | Histones | 1 | 2021 | 588 | 0.130 |
Why?
| | Transcriptional Activation | 1 | 2018 | 366 | 0.130 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 118 | 0.130 |
Why?
| | Humans | 17 | 2024 | 129847 | 0.130 |
Why?
| | Hematopoiesis | 1 | 2017 | 184 | 0.120 |
Why?
| | Mutation | 3 | 2024 | 3706 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1686 | 0.120 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2015 | 14 | 0.120 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2016 | 190 | 0.120 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2021 | 596 | 0.120 |
Why?
| | beta Catenin | 1 | 2016 | 224 | 0.120 |
Why?
| | Nerve Tissue Proteins | 1 | 2018 | 569 | 0.120 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2015 | 191 | 0.110 |
Why?
| | Cells, Cultured | 1 | 2022 | 4102 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2021 | 1900 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 2 | 2017 | 634 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2018 | 1119 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4077 | 0.100 |
Why?
| | Leukemia, B-Cell | 1 | 2011 | 14 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2011 | 21 | 0.090 |
Why?
| | Melanoma | 1 | 2018 | 730 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2011 | 319 | 0.080 |
Why?
| | Repressor Proteins | 1 | 2011 | 404 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2018 | 753 | 0.070 |
Why?
| | K562 Cells | 2 | 2018 | 85 | 0.070 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 999 | 0.070 |
Why?
| | Cell Lineage | 2 | 2021 | 332 | 0.070 |
Why?
| | Nuclear Proteins | 1 | 2011 | 660 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2020 | 10241 | 0.060 |
Why?
| | Cell Survival | 2 | 2018 | 1086 | 0.050 |
Why?
| | Gene Expression | 2 | 2021 | 1465 | 0.050 |
Why?
| | Cell Line | 2 | 2021 | 2780 | 0.050 |
Why?
| | Bone Marrow | 1 | 2024 | 272 | 0.050 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 2021 | 7 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1560 | 0.050 |
Why?
| | Disease Progression | 2 | 2018 | 2628 | 0.040 |
Why?
| | Dexamethasone | 1 | 2023 | 352 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2021 | 142 | 0.040 |
Why?
| | Pyridines | 1 | 2023 | 478 | 0.040 |
Why?
| | Signal Transduction | 3 | 2018 | 4935 | 0.040 |
Why?
| | Philadelphia Chromosome | 1 | 2018 | 18 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 697 | 0.040 |
Why?
| | Semaphorins | 1 | 2018 | 28 | 0.040 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2018 | 40 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2018 | 253 | 0.040 |
Why?
| | Mice, SCID | 1 | 2018 | 350 | 0.030 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2017 | 14 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2017 | 18 | 0.030 |
Why?
| | Antigens, CD34 | 1 | 2017 | 88 | 0.030 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2016 | 21 | 0.030 |
Why?
| | Mice, Nude | 1 | 2018 | 680 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2016 | 75 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2016 | 70 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 5468 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 587 | 0.030 |
Why?
| | Transfection | 1 | 2018 | 918 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 96 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2018 | 590 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 66 | 0.030 |
Why?
| | Drug Synergism | 1 | 2016 | 370 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 577 | 0.030 |
Why?
| | DNA Replication | 1 | 2017 | 225 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2015 | 75 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 611 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 2016 | 164 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2015 | 141 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2016 | 931 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 194 | 0.030 |
Why?
| | Small Molecule Libraries | 1 | 2015 | 86 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2015 | 266 | 0.030 |
Why?
| | Trans-Activators | 1 | 2017 | 392 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2015 | 179 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2015 | 483 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2018 | 957 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2016 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 2022 | 0.020 |
Why?
| | Inflammation | 1 | 2021 | 2748 | 0.020 |
Why?
| | Models, Molecular | 1 | 2015 | 1488 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3773 | 0.020 |
Why?
| | Databases, Factual | 1 | 2015 | 1269 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2545 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 6550 | 0.020 |
Why?
| | Adult | 1 | 2023 | 35634 | 0.010 |
Why?
| | Female | 1 | 2018 | 68829 | 0.010 |
Why?
| | Male | 1 | 2015 | 63759 | 0.000 |
Why?
|
|
De Dominici's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|